Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...
Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...
“BIOHAZARDS AT HARVARD,” warns the cover of the June 8, 1976 issue of the Boston Phoenix. “Scientists are on the brink of undertaking revolutionary genetic research which creates new life forms,” the ...
This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
insights from industryAmy ShengHead of CROSino Biological In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO program at Sino Biological US Inc., about current developments in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback